Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment through advanced 3D modeling techniques.
As placebo spoils PhIII trial, Acadia does not intend to stage further Nuplazid studies in schizophrenia
After years of trying to expand the market territory for Nuplazid, Acadia Pharmaceuticals might have hit a dead end, with a Phase III failure in
March 13, 2024